OncoMatch/Clinical Trials/NCT06717750
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Official title: A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
Is NCT06717750 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies CSCJC3456 tablet for advanced malignant solid tumors.
Treatment: CSCJC3456 tablet — This is a multicenter, open-label, phase I clinical study employing a dose-escalation and cohort-expansion design to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Allowed: FGFR4 expression
Cohort A (hepatocellular carcinoma, including at least 2 participants with FGFR4 positivity)
Allowed: FGFR1 expression
Cohort B (colorectal cancer, including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 expression
Cohort B (colorectal cancer, including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR1 expression
Cohort C (gastric cancer (including adenocarcinoma at the gastroesophageal junction), including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 expression
Cohort C (gastric cancer (including adenocarcinoma at the gastroesophageal junction), including at least 2 participants with FGFR1 or FGFR2 positivity)
Allowed: FGFR2 expression
Cohort D (recurrent/metastatic endometrial cancer, including at least 2 participants with FGFR2 or FGFR3 positivity)
Allowed: FGFR3 expression
Cohort D (recurrent/metastatic endometrial cancer, including at least 2 participants with FGFR2 or FGFR3 positivity)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: FGFR inhibitor (pemetrexed, erdafilone, infigranib, forodesine, ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2874455, BAY1163877)
Previously received treatment with FGFR inhibitors (e.g., pemetrexed, erdafilone, infigranib, forodesine, ponatinib, dovitinib, nintedanib, AZD4547, NVP-BGJ398, LY2874455, BAY1163877, etc.)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate Organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06717750 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FGFR inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify